Introduction
Pancreatic cancer is a highly metastatic cancer characterized by widespread intraperitoneal dissemination and ascites formation, which frequently occur even after curative resection and are the major cause of death in pancreatic cancer patients (1, 2) . Thus, the elucidation of the mechanisms underlying peritoneal dissemination is of great importance to develop novel tools to treat pancreatic cancer. Peritoneal dissemination is thought to be composed of several processes, including cell adhesion, migration, invasion and proliferation (3, 4) . Lysophosphatidic acid (LPA), one of the simplest natural phospholipids, is a lipid mediator that evokes hormone-and growth factor-like responses in almost every cell type. Five subtypes of G-protein-coupled LPA receptors (LPA 1 -LPA 5 ) have been identified so far (5) (6) (7) . LPA elicits diverse cellular responses, including proliferation, survival, morphological change and motility. LPA has been shown to be present in various biological fluids, including malignant ascites (8) (9) (10) , and implicated in the cancer initiation, progression and metastasis (11) (12) (13) .
We have developed an LPA receptor antagonist, Ki16425, which shows a preference for LPA 1 and LPA 3 over LPA 2 (14) . Using the LPA-specific antagonist, Ki16425, and LPA 1 -specific small interfering RNA (siRNA), we have recently demonstrated that LPA in the malignant ascites from pancreatic cancer patients is an active component that stimulates the migration and invasion of pancreatic cancer cells, including Panc-1 and YAPC-PD, through LPA 1 receptors (10) . The stimulatory role of LPA 1 receptors for cell migration is recognized in a variety of cell types, although LPA 1 receptors seem to mediate the inhibition of migration of T lymphocytes (15) . For example, DLD1 colon cancer cells (16) and GNS-3314 and CGNH-89 glioblastoma cells (17) respond to LPA, resulting in the stimulation of migration through LPA 1 receptors. Hama et al. (18) have shown that LPA 1 receptors mediate migration of SF295 glioblastoma cells, MDA-MB-231 breast cancer cells, PC-3 prostate cancer cells and A-2058 melanoma cells in response to LPA and autotaxin, an LPAproducing enzyme. Ki16425 has been shown to inhibit migration response to LPA in cancer cells that express a larger amount of LPA 1 receptors than other LPA receptor subtypes (10, 17, 18 2 receptors, in addition to LPA 1 receptors, are significantly expressed; however, the role of LPA 2 receptors remains unknown (10) .
In the present study, we extended the previous study and examined the effects of Ki16425 on the change in pancreatic cancer cell motility by LPA and ascites. Consistently with the previous study (10) , Ki16425 potently inhibited the migration response to LPA and ascites in the pancreatic cancer cells. Unexpectedly, however, we observed that both LPA and ascites inhibited epidermal growth factor (EGF)-induced migration in the presence of Ki16425. This result suggests that LPA-rich ascites has the potential not only to stimulate but also to inhibit cell migration. We characterized the mechanisms underlying LPA-and ascites-induced inhibitory migration and found that the LPA 2 receptor/RhoA-signaling pathways mediate the inhibitory response to LPA and ascites when the functions of LPA 1 receptors and/or G i proteins are blocked.
Materials and methods
Materials 1-Oleoyl-sn-glycero-3-phosphate (LPA) was purchased from Cayman Chemical Co. (Ann Arbor, MI); fatty acid-free bovine serum albumin (BSA) was from Calbiochem-Novabiochem Co. (San Diego, CA); pertussis toxin (PTX) was from List Biological Laboratories (Campbell, CA); EGF was from SigmaAldrich (St Louis, MO); EZ-Detect Activation Kit for RhoA was from PIERCE (Rockford, IL) and monoglyceride (MG) lipase was from Asahi Kasei Corp.
(Shizuoka, Japan). Ki16425 (3-(4-[4-([1-(2-chlorophenyl) ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid) was synthesized by Kirin Brewery Co. (Takasaki, Japan) (14) . The complementary DNA coding C3 toxin and T19NRhoA were generously gifted from Dr Shuh Narumiya of Kyoto University (Kyoto, Japan) and Dr Kozo Kaibuchi of Nagoya University (Nagoya, Japan), respectively. The sources of all other reagents were the same as described previously (10, (20) (21) (22) (23) .
Ascites from cancer patients
The ascites was prepared from pancreatic cancer patients at the Division of Thoracic and Visceral Organ Surgery, Gunma Graduate University School of Medicine, from 2001 to 2003. Informed consent was obtained from each patient for the use of samples. Ascites was collected in the presence of ethylenediaminetetraacetic acid (at a final concentration of 2-3 mM) and centrifuged at 1000g for 20 min to remove cells as described previously (10) . The cell-free fluid was stored at À80°C until use. In the present study, we used the same ascites as those used in the previous study (10) . The ascites A1, A2 and A3 used in the present study corresponds to the ascites from case 2, case 3 and case 4, in the previous study, respectively. Their LPA levels evaluated by a bioassay based on the ability to inhibit cyclic adenosine 3#,5#-monophosphate accumulation in LPA 1 -expressing RH7777 cells were 534 nM for case 2, 2318 nM for case 3 and 6637 nM for case 4, respectively (10).
Cell culture
Human pancreatic cancer cell lines, Panc-1 and PK-1, were kindly provided by the Cancer Cell Repository, Tohoku University (Sendai, Japan), and BxPC-3 and CFPAC-1 were purchased from the American Type Culture Collection (Rockville, MD). YAPC-PD pancreatic cancer cell line was established from the pancreatic cancer patient (10) . All pancreatic cancer cell lines were cultured in RPMI 1640 containing 10% fetal bovine serum. Twenty-four hours before the experiments, the medium was changed to a fresh medium (without serum) containing 0.1% (wt/vol) BSA (fraction V) unless otherwise specified. Where indicated, PTX (100 ng/ml) was added to the culture medium 24 h before the experiments.
Construction of adenoviral vector and infection of recombinant adenovirus
The recombinant adenovirus containing the regulators of G-protein signaling (RGS) domain of p115RhoGEF (p115RGS), C3 toxin and the dominantnegative RhoA (T19NRhoA) was constructed as described previously (24) . The adenovirus expressing green fluorescent protein was used for controls. For the infection with recombinant adenoviruses, pancreatic cancer cells were plated on 6 or 10 cm dishes. When the cells had become 90% confluent, the culture medium was changed to Dulbecco's modified Eagle's medium with 5% fetal bovine serum containing adenovirus at a multiplicity of infection of 10-100. After incubation for 1 h at 37°C, the infection was terminated by adding an excess amount of a fresh medium containing 0.1% BSA and further cultured for 2 days. The cells were used for subsequent application as shown below. See refs (21, 22) for more details.
Transfection of siRNA Pancreatic cancer cell lines were plated on 6 cm dishes. Sixteen hours later, siRNAs (final 3 nM) were introduced into cells using an RNAiMAX reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions and the cells were further cultured for 24 h. The LPA receptor messenger RNA (mRNA) level was measured using real-time TaqMan technology, and a cell migration assay was performed 24 h after serum starvation as described later. The siRNA for LPA 1 (siLPA 1 , L-003656), siRNA for LPA 2 (siLPA 2 , L-004602) and non-silencing RNA (NS, D-001810-10) were obtained from Dharmacon (Lafayette, CO).
Quantitative reverse transcription-polymerase chain reaction using real-time TaqMan technology Total RNA was isolated using TRI REAGENT (Sigma-Aldrich) according to the instructions from the manufacturer. After DNase I (Promega, Madison, WI) treatment to remove possible traces of genomic DNA contaminating in the RNA preparations, 5 lg of the total RNA was reverse transcribed using random priming and Multiscribe reverse transcriptase according to the instructions from the manufacturer (Applied Biosystems, Foster City, CA). To evaluate the expression level of the LPA 1 , LPA 2 , LPA 3 , LPA 4 and LPA 5 mRNAs, quantitative reverse transcription-polymerase chain reaction was performed using real-time TaqMan technology with a Sequence Detection System model 7700 (Applied Biosystems). The human LPA 1 (Hs00173500)-, LPA 2 (Hs01109356)-, LPA 3 (Hs00173857)-, LPA 4 (Hs00271072)-, LPA 5 (Hs00252675)-and glyceraldehydes 3-phosphate dehydrogenase (4352934E)-specific probes were obtained from TaqMan gene expression assays (Applied Biosystems). Other experimental conditions were described previously (10) . The expression level of the target mRNA was normalized to the relative ratio of the expression of glyceraldehydes 3-phosphate dehydrogenase mRNA. Each reverse transcription-polymerase chain reaction assay was performed at least three times, and the results are expressed as mean ± SE.
MG lipase treatment LPA (10 lM), EGF (100 ng/ml) or ascites (10%) was treated with MG lipase (10 U/ml) for 30 min at 37°C in RPMI 1640 containing 0.1% BSA. In separate experiments, we added [ 3 H]LPA to the assay medium and confirmed that .98% of LPA in the test samples was degraded under these conditions (10) . These MG lipase-treated samples were finally used by 10 times dilution with the assay medium.
Cell migration assay
The migration experiment was performed using a modified Boyden chamber apparatus, as described previously (10) . In brief, Panc-1 cells and other cancer cells were harvested with 0.05% trypsin containing 0.02% ethylenediaminetetraacetic acid, washed once and resuspended with RPMI 1640 containing 0.1% BSA. The cells (1 Â 10 5 /100 ll) were loaded into the upper chamber, and test agents were placed in the lower chamber, unless otherwise specified. A membrane filter with 8 lm pore was precoated overnight at 4°C with 100 lg/ml rat tail collagen. Under the precoating condition, pore of the filter is still open and, therefore, the cells can migrate toward the agents existing in the lower chamber. When the effect of Ki16425, an LPA antagonist, was examined, the cells were preincubated for 10 min with the antagonist before loading. The number of cells that had migrated for 4 h to the lower surface was determined by counting the cells in four places under microscopy at Â400 magnification.
Matrigel invasion assay
Cell invasion activity was assessed by using a Matrigel invasion chamber (BD Biosciences, San Jose, CA) according to the instructions provided by the manufacturer. The cells (7.5 Â 10 4 /750 ll) were loaded on the transwell chamber (8 lm pore) covered with growth factor-reduced Matrigel and test agents were placed in the lower chamber. The number of the cells that migrated to the lower surface during a 24 h-incubation was determined as described above. In this assay system, the pore filter is covered with a thin layer of Matrigel and, therefore, the cells have to digest Matrigel in order to reach the lower chamber. Thus, we can evaluate the in vitro invasive activity of cancer cells, which is associated with digestion of matrix protein, by this assay.
Estimation of RhoA activation by a pull-down assay
The cells were treated with PTX or siLPA 2 , as described above. The cells were washed once, preincubated for 10 min with or without 3 lM Ki16425 at 37°C in a N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid -buffered medium composed of 20 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid, pH 7.4, 134 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 2 mM CaCl 2 , 2.5 mM NaHCO 3 , 5 mM glucose and 0.1% BSA and then incubated with test agents for 5 min at 37°C. The incubation was terminated by washing twice with ice-cold phosphate-buffered saline and adding 0.8 ml of a lysis buffer according to the instruction manual of RhoA Activation Kit (PIERCE). The recovered fractions were subjected to the western blot analysis, as described previously (17) .
Western blotting analysis of DN-Rho and p115RGS
For analysis of the expression of protein bands of the dominant-negative RhoA and p115RGS, reaction was terminated by washing twice with ice-cold phosphate-buffered saline and adding 0.12 ml of lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 8 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 25 mM NaF, 10 mM Na 4 P 2 O 7 , 1 mM Na 3 VO 4 , 5 lg/ml leupeptin, 5 lg/ml pepstatin, 5 lg/ml aprotinin and 0.5 mM phenylmethylsulfonyl fluoride. The lysate was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by western blotting with specific antibodies to RhoA, p115RhoGEF (Santa Cruz Biotechnology, Santa Cruz, CA) and p115RGS (24) .
Cell viability and adhesion assay
The cells were treated with PTX and/or siLPA 2 , as described above, and, the living cell number was measured by the 3-(4,5-dimethythiazol-2-yl)-diphenyltetrazolium bromide (MTT) reduction assay (Chemicon International, Temecula, CA) (10) to see the effect of PTX and siLPA 2 on cell viability. In a separate experiment, the cells were harvested by trypsin, seeded on 24-well collagen-coated plates at a density of 2 Â 10 4 cells per well in RPMI 1640 containing 0.1% BSA and test agents and then further incubated for 4 h. Floating cells were aspirated, plates were rinsed with phosphate-buffered saline and the attached cells were then evaluated by MTT.
Data presentation
All experiments were performed in duplicate or triplicate. The results of multiple observations are presented as the mean ± SE or as representative results
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from more than three different batches of cells, unless otherwise stated. Statistical significance was assessed by analysis of variance or the Student's t-test; values were considered significant at P , 0.05 ( Ã ).
Results
Ki16425 modulates the migratory activity of Panc-1 cells in response to malignant ascites from pancreatic cancer patients and LPA Consistent with the previous study (10) , LPA and malignant ascites from pancreatic cancer patients stimulated the migration of Panc-1, a pancreatic cancer cell line ( Figure 1A , left panel), and the stimulatory migration response to LPA and ascites was markedly inhibited by Ki16425, an LPA 1 and LPA 3 antagonist ( Figure 1B, left panel) . EGF also stimulated the cell migration maximally, and the EGF-induced activity was not further enhanced by LPA or ascites ( Figure 1A , right panel). Unexpectedly, however, LPA and ascites significantly inhibited the EGF-induced migration in the presence of Ki16425 ( Figure 1B, right panel) . Thus, LPA and ascites have the potential not only to stimulate but also to inhibit the migration response of Panc-1 cells. We have shown previously that MG lipase, an LPAdegrading enzyme, inhibited the stimulatory migration response to LPA and ascites (10) . As shown in Figure 1C , prior treatment of LPA and ascites with MG lipase reversed their inhibitory migration activity in the presence of EGF, suggesting that not only stimulatory but also inhibitory actions of ascites on the migration response are mediated by LPA existing in the ascites. Both stimulatory and inhibitory actions were observed at a similar range of LPA concentrations ( Figure 1D ). In the present study, we used 1-10% ascites, in which LPA exists at the concentrations of $0.005-0.66 lM (see Materials and Methods), which is enough to significantly exert both a stimulatory and an inhibitory migration responses.
LPA 1 receptors stimulate, whereas LPA 2 receptors inhibit, the migration of Panc-1 cells In Panc-1 cells, LPA 1 and LPA 2 are major LPA receptor subtypes ( Figure 2A ). In order to examine the roles of the LPA receptor subtypes in the migration response, an siRNA strategy was employed: the respective siRNAs against the LPA 1 and LPA 2 receptors specifically inhibited their mRNA expression ( Figure 2B ). Under the conditions, siRNA specific to LPA 1 receptors (siLPA 1 ) markedly inhibited the stimulatory migration response to LPA and ascites ( Figure 2C , middle panel), whereas the siRNA specific to LPA 2 (siLPA 2 ) was ineffective for inhibiting the stimulatory action ( Figure 2C , right panel). These results support the notion that the stimulatory migration response is mediated by LPA 1 receptors but not by LPA 2 receptors. Similarly to the Ki16425-treated cells shown in Figure 1B , LPA and ascites inhibited EGF-induced migration in the siLPA 1 -treated cells, whereas siLPA 2 had no appreciable effect on the migration response to any of the agents employed ( Figure 2C ). The lack of the significant effect by siLPA 2 , however, does not mean that the LPA 2 receptor has no ability to regulate the migration activity. The inhibitory migration response was also observed when the cells were treated with PTX, which inhibits the function of G i proteins ( Figure 2D , left panel). These results suggest that the allowance of LPA and ascites to inhibit the migration response to EGF requires the blockage of the LPA 1 receptor/G i protein system. On the other hand, treatment of the cells with siLPA 2 , but not with siLPA 1 , almost completely reversed the inhibitory migration response induced by LPA and ascites in the PTX-treated cells ( Figure 2D ). Similarly, siLPA 2 also reversed the inhibitory activity of LPA and ascites in the presence of Ki16425 ( Figure 2E ). These results suggest that LPA 2 receptors mediate the LPA-and Inhibition of cancer cell motility by LPA and ascites ascites-induced inhibitory migration response. The specificity of the siLPA 2 was confirmed in Figure 2F . Sphingosine 1-phosphate (S1P), although small when compared with LPA, similarly inhibited the migratory response to EGF in the PTX-treated cells ( Figure 2F, left panel) . Unlike LPA, however, the S1P-induced inhibition of the migration response was hardly affected by the siLPA 2 treatment.
The role of the inhibitory migration activity of LPA 2 receptors was confirmed by the LPA 2 agonist, LP-105, which has been reported to also have a weak antagonistic activity for LPA 1 and LPA 3 receptors (25) . The LPA derivative inhibited the EGF-induced migration response in PTX-treated cells (supplementary Figure 1A is available at Carcinogenesis Online). The inhibitory activity of LP-105 was, as expected, attenuated by siLPA 2 treatment (supplementary Figure 1B is available at Carcinogenesis Online).
Involvement of G 12/13 proteins and RhoA in the inhibitory action via LPA 2 receptors Recent studies have suggested that G 12/13 proteins mediate the inhibitory migration response to S1P through S1P 2 receptors (26). Since LPA 2 receptors are known to be coupled to G 12/13 proteins (5), we examined the role of G 12/13 proteins on the inhibitory migration response. The RGS domain of p115RhoGEF has been shown to interact with Ga 12 or Ga 13 , resulting in the inhibition of Ga 12 or Ga 13 signaling (27) . As shown in Figure 3A , p115RGS did not affect the stimulatory action of LPA. However, the inhibitory LPA action in the presence of EGF in the PTX-treated cells ( Figure 3B , left panel) was attenuated by p115RGS ( Figure 3B, right panel) , suggesting the involvement of G 12/13 proteins in the LPA 2 receptor signaling. The expression of p115RGS protein without change in the p115Rho-GEF protein was confirmed in Figure 3C . In order to shut down the Ã The effects of the respective siRNAs on the LPA receptor mRNA expression were significant. (C) Panc-1 cells were treated with non-silencing RNA (NS), siLPA 1 or siLPA 2 and then the cells were assayed to measure migration response to vehicle (None), 1 lM LPA or 10% ascites in the presence or absence of 10 ng/ml EGF. (D) Experimental conditions were exactly the same as those for (C) except that the cells were treated for 24 h with 100 ng/ml PTX. (E) Panc-1 cells were treated with non-silencing RNA (NS) or siLPA 2 . The cells were incubated for 10 min with 3 lM Ki16425 and then migration response to the indicated agents was measured. Other experimental conditions were the same as those for (C). (F) Panc-1 cells were treated with non-silencing RNA (NS) or siLPA 2 and then treated with PTX as (D). The cells were incubated to measure migration response to vehicle (None), 1 lM LPA or 1 lM S1P in the presence or absence of 10 ng/ml EGF. In (C-F), the results are expressed as migrated cell numbers as described in Figure 1 . Data are the means ± SEs of three or four separate experiments.
Ã The effect of LPA, ascites or S1P in the presence of EGF was significant in (C-F).
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downstream signaling pathways of G 12/13 proteins, we employed a dominant-negative form of the RhoA gene (DN-RhoA), T19N-RhoA and C3 toxin genes. Neither DN-RhoA nor C3 toxin affected the LPA-induced stimulation of migration ( Figure 3D ), whereas both DN-RhoA and C3 toxin attenuated the LPA-induced inhibition of the migration response to EGF ( Figure 3E ). The expression of DNRhoA protein was confirmed by the increase in the band recognized by the RhoA antibody in Figure 3F . These results suggest that G 12/13 proteins and RhoA are responsible for the inhibitory migration response without having an appreciable impact on the stimulatory migration response.
LPA activates RhoA through the LPA 2 receptor As shown in Figure 4A , LPA but not EGF stimulated formation of GTP-RhoA, an active form of RhoA, as measured by a pull-down assay. The LPA-induced RhoA activation was not appreciably affected by the treatment of the cells with either Ki16425 or PTX regardless of the presence of EGF ( Figure 4A ). On the other hand, siLPA 2 treatment inhibited the LPA-induced RhoA activation ( Figure 4B ). These results suggest that LPA activates RhoA through the LPA 2 receptor regardless of the activation state of the LPA 1 receptor/G i protein.
Involvement of the LPA 2 receptor in the inhibition of migration of pancreatic cancer cell lines In Figure 5 , we examined the migration activity in pancreatic cancer cell lines, including YAPC-PD, BxPC-3, CFPAC-1 and PK-1, other than Panc-1. Although the expression profile of LPA receptor subtypes varies from cell to cell in all pancreatic cell lines (10), the mRNA expression of both LPA 1 and LPA 2 receptors is commonly observed (Figure 5A-D) . Moreover, both LPA and EGF stimulated cell migration, PTX treatment abolished the LPA-induced migration activity without having any significant effect on the EGF-induced action and finally LPA significantly inhibited EGF-induced migration in the PTX-treated cells. The role of LPA 2 receptors in the inhibitory LPA action was confirmed by the siLPA 2 treatment: LPA-induced 
LPA inhibits Matrigel invasion in the cells treated with PTX
Proteolysis of extracellular matrix proteins is an important step for the invasion and metastasis of cancer cells. The possibility that LPA inhibits the invasion of pancreatic cancer cells was studied using a Matrigel invasion assay. Panc-1 cells were loaded on Matrigelcoated pore filters for 24 h in the absence or presence of EGF or LPA in the lower chamber, and the cells that had migrated to the lower surface of the filters were counted. Consistently with the migration activity, LPA stimulated invasion and its activity was blocked by PTX treatment ( Figure 6A and B) ; LPA inhibited EGF-induced invasion in the PTX-treated cells ( Figure 6B ) and moreover, the LPA-induced inhibition of invasion was attenuated by treatment of the cells with siLPA 2 but not with siLPA 1 (Figure 6C and D) , suggesting that LPA, through LPA 2 receptors, also has the potential to inhibit invasion in PTX-treated cells.
Viability and adhesion activity of the cells are not regulated by LPA, ascites and other agents, which modulate the motility activity We finally examined if agents used in the present study changed the viability and adhesion activity of the cells rather than their invasive property and thereby affected the migration and invasive activity of the cells. For this purpose, the cells were treated with PTX and/or siLPA 2 . The treatment of the cells with PTX and/or siRNA hardly affected their viability, as assessed by MTT reduction assay (supplementary Figure 2A is available at Carcinogenesis Online). A part of the cells were harvested and seeded on the collagen-coated plates in the presence or absence of LPA, ascites, EGF and Ki16425. Four hours later, attached cell numbers were measured by the MTT assay. As shown in supplementary Figure 2B (available at Carcinogenesis Online), the adhesion activity was hardly affected by the agents employed. Thus, it is unlikely that the agents employed in the present study affected motility of the cells by changing cell viability and adhesion activity.
Discussion
Ki16425 is an LPA 1 and LPA 3 antagonist (14) . Consistently with the previous study (10) , the LPA antagonist inhibited the migration of pancreatic cancer cells by malignant ascites from pancreatic cancer patients. Unexpectedly, however, the ascites inhibited EGF-induced migration in the presence of the LPA antagonist. The present report, to our knowledge, is the first indication that potent migration-stimulating ascites also has the potential to inhibit the migration activity of invasive pancreatic cancer cells. The elucidation of the inhibitory mechanism of cancer cell migration by ascites may provide a novel insight into the control of migration and, hence, invasion and metastasis of cancer cells.
The component of ascites that contributes to the inhibition of cell migration may be LPA. Indeed, LPA mimicked the ascites-induced inhibition of migration in the presence of Ki16425. The ascites-and LPA-induced inhibition of migration response to EGF was suppressed by MG lipase, an LPA-degrading enzyme. Moreover, the inhibitory response to ascites and LPA was attenuated by siRNA specific to LPA 2 receptors, suggesting that LPA 2 receptors mediate the inhibitory action. The inhibition of migration by LPA is also uncommon, but this is not the first report. Recently, Takuwa et al. reported that LPA inhibited the insulin-like growth factor-I-induced migration of Chinese hamster ovary (CHO) cells when the function of G i proteins was inhibited by PTX, whereas LPA stimulated cell migration in the absence of the Figure 2D . The cells were then assayed for RhoA activity as described in (A). The results were the representative of three separate experiments.
M. Komachi et al. toxin treatment (28). Jaganathan et al. (29) recently reported that LPA induces divergent migration responses depending on the activation status of Rho in human mesenchymal stromal cells. LPA inhibited the migration response in association with the activation of RhoA, whereas this was reversed to an induction of migration by LPA when RhoA was inactivated by the C3 toxin. In human mesenchymal stromal cells, LPA 1 and LPA 2 receptors are expressed; however, the role of the LPA receptor subtypes in the migration responses has not been examined in experiments (29) .
In the CHO cell system, LPA 1 receptors seem to mediate both the stimulatory and the inhibitory action (28) . In our pancreatic cancer cell system, however, LPA 2 receptors, rather than LPA 1 receptors, mediate the inhibitory action, whereas LPA 1 receptors mediate the stimulatory action. First, in pancreatic cancer cells, LPA 1 , LPA 2 and LPA 3 receptors are significantly expressed. As reported above, LPA 2 -siRNA, but not LPA 1 -siRNA, attenuated the LPA-induced inhibition of the migration response to EGF. Second, an LPA 2 receptor agonist, LP-105, inhibited the EGF-induced migration response. Third, the Ã The effect of LPA in the presence of EGF was significant. Ã The effect of LPA in the presence of EGF was significant.
Inhibition of cancer cell motility by LPA and ascites inhibitory LPA action was observed in the presence of an LPA 1 and LPA 3 antagonist, Ki16425, suggesting that the inhibitory action is mediated by neither LPA 1 nor LPA 3 receptors. Finally, LPA 1 -siRNA allowed LPA to inhibit EGF-induced migration, whereas the siRNA inhibited the LPA-induced stimulatory migration response.
Although the LPA receptor subtype involved in the inhibitory migration response was different, the mechanisms leading to the inhibition of migration by LPA were very similar in CHO cells and Panc-1 cells. The inhibitory LPA action in the pancreatic cancer cells was attenuated by p115RGS, an RGS domain of p115RhoGEF that specifically blocks Ga 12 or Ga 13 signaling; C3 toxin, a toxin that specifically deactivates Rho and T19NRhoA, the dominant-negative RhoA. This suggests that LPA inhibits the EGF-induced migration response through the G 12/13 protein/Rho-signaling pathways, which is essentially the same signaling cascade for the LPA 1 -mediated inhibition of migration in PTX-treated or G i protein-inactivated CHO cells (28) . Both LPA 1 and LPA 2 receptors have been shown to be coupled to G 12/13 proteins, which may cause Rho activation (5, 12) . Although previous studies showed that Rho is required for a migration response to a variety of growth factors (30) (31) (32) , strong activation of Rho, via S1P 2 receptor-mediated G 12/13 protein activation, induces the inhibition of migration of CHO cells (33) , B16 melanoma cells (34) , glioblastoma cells (22, 35) , mouse embryo fibroblasts (36) and vascular smooth muscle cells (37) . The activation of Rho induced by melatonin (38) and oligodendrocyte lineage transcription factor 2 (OLIG2) (39) has also been shown to inhibit the migration of MCF-7 breast cancer cells and U12-1 glioma cells, respectively. Consistently with the inhibitory role of Rho GTPase in cell migration, cyclin D1 has been shown to stimulate the migration of mouse embryo fibroblasts in association with the inhibition of Rho/Rho kinase (40, 41) . Moreover, a Rho inhibitor, C3 toxin and a Rho kinase inhibitor, Y27632, have been shown to stimulate the migration of astrocytoma cells (42) and mouse hematopoietic progenitor cells (43) .
The activation of Rho may be induced by several GTP-binding regulatory protein-coupled receptors; however, only S1P 2 receptors (22, (33) (34) (35) (36) (37) and LPA 1 receptors (28) have been known to be able to inhibit cell migration. Based on the results of the present study, the LPA 2 receptor may be listed as a third GTP-binding regulatory protein-coupled receptor to inhibit cell migration through the G 12/13 protein/Rho-signaling pathways. The LPA-induced inhibition of the migration response to EGF in the G i protein-inactivated Panc-1 cells was almost completely reversed by siLPA 2 but not by siLPA 1 ( Figure  2D ). Thus, in contrast to CHO cells, the LPA 1 receptor is unable to inhibit the migration response in pancreatic cancer cells even under G i protein-inactivated conditions. The difference in the LPA 1 receptor expression level and its coupling efficiency to the effectors may explain the difference in the LPA 1 -mediated responses between the two cell lines. In any event, in order to detect the inhibitory LPA action, some specific modifications of the cells, i.e. inactivation of either LPA 1 receptors or G i proteins, are required. This may be the reason why the inhibitory role of LPA 2 receptors was missing in the previous study.
However, it remains uncharacterized why the inhibitory action through the LPA 2 receptor/G 12/13 protein/Rho signaling on the Rac-mediated migration response requires inactivation of the LPA 1 receptor/G i protein signaling. LPA-induced Rho activation was inhibited by siLPA 2 but was not affected by Ki16425 and PTX, suggesting that the LPA 1 receptor/G i protein signaling may modulate the downstream signaling of Rho rather than the LPA 2 receptor-mediated Rho activation step. Although we have not measured the Rac activity in the present study, in the CHO cell system characterized by Sugimoto et al. (28) , Rac activity is positively regulated by G i proteins and negatively regulated by the G 12/13 protein/Rho, although the downstream signaling leading to Rac inhibition by Rho remains unknown (26) . Thus, they showed that, in the presence of functional G i proteins, the negative signal is masked by the positive signal at the Rac activation step.
Although the further investigation is required to determine the mechanism underlying the LPA 2 receptor-mediated inhibition of migration response, the result of the present study may justify the usage of LPA 1 antagonists against the invasion and metastasis of cancer cells. In the cells expressing both LPA 1 and LPA 2 receptors, LPA 1 antagonists and/or G i protein inhibitors are expected to not only inhibit LPA 1 -mediated stimulation of migratory activity but also allow LPA, through LPA 2 receptors, to inhibit the migration in response to growth factors. In other words, LPA becomes the inhibitory modulator for cancer cell motility in the presence of LPA 1 antagonists or G i protein inhibitors. LPA 1 and LPA 2 receptors are recognized to be widely expressed in a variety of cancer cells (11) (12) (13) , including pancreatic cancer cells (10) and glioma cells (17, 18) . In the present study, even though we investigated only the pancreatic cancer cell line, all five strains of the cells examined showed the inhibitory migration response to LPA through LPA 2 receptors under G i protein-inactivated conditions. Although it remains uncharacterized whether or not the inhibition of motility of pancreatic cancer cells through LPA 2 receptors occurs in vivo, Ki16425 has been shown to effectively attenuate the in vivo bone metastases (44) . The in vivo effects of Ki16425 on the intraperitoneal dissemination and metastasis of pancreatic cancer cells are our current project.
In conclusion, blockage of LPA 1 receptors and/or G i proteins allows malignant ascites and LPA to actively inhibit the motility of pancreatic cancer cells through the LPA 2 receptor/G 12/13 protein/ Rho-signaling pathways. Supplementary Figures 1 and 2 can be found at http://carcin. oxfordjournals.org/ 
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